Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make ...

Maureen is a Medical Director/Medical Consult and Review Physician in Infectious Disease and Vaccines for Merck. She received her medical degree ... She has been in practice for more than 20 years ...

A major trial testing multiple sclerosis drug evobrutinib failed in December last year. Merck, which previously predicted ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...